SCHEMBL6643012

SCHEMBL6643012

Cc1ccc(C(=O)O)c(N2CCC(C)CC2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.54
GAA P10253 3/20 0.52
KDM4E B2RXH2 2/20 0.52
POLB P06746 2/20 0.52
NR4A1 P22736 1/20 0.52
HSD17B10 Q99714 1/20 0.52
KMT2A Q03164 1/20 0.49
USP2 O75604 1/20 0.49
MAPT P10636 3/20 0.48
TP53 P04637 3/20 0.48
THRB P10828 1/20 0.48
LMNA P02545 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HPGD P15428 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16448842 0.88 HTT (0.65) HTTGAAKDM4EPOLBNR4A1
SCHEMBL6643603 0.84 GAA (0.49) GAAKDM4EPOLBHSD17B10KMT2A
SCHEMBL6646051 0.83 GAA (0.51) GAAKDM4EPOLBHSD17B10KMT2A
SCHEMBL6646771 0.83 GAA (0.51) GAAKDM4EPOLBHSD17B10KMT2A
SCHEMBL7199389 0.82 MAPT (0.50) GAAKDM4EPOLBKMT2AMAPT
SCHEMBL6647782 0.81 THRB (0.53) GAAKDM4EPOLBNR4A1HSD17B10
SCHEMBL6646448 0.81 NPC1 (0.47) HTTGAAKDM4EPOLBHSD17B10
SCHEMBL6647058 0.81 HTT (0.51) HTTGAAKDM4EPOLBNR4A1
SCHEMBL7195094 0.80 MAPT (0.50) HTTGAAKDM4EPOLBNR4A1
SCHEMBL27358323 0.80 HCRTR1 (0.40) HTTGAAKDM4EKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR HTT 1332/4885GAA 3155/4885KDM4E 3725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.